ASCO 2014: Dr. Walter M. Stadler gives his top picks in genitourinary research

1. Abstract LBA2, Christopher Sweeney et al.

Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): An ECOG-led phase III randomized trial.

http://abstracts.asco.org/144/AbstView_144_127755.html

2. Abstract 5012, Toni K. Choueiri et al.

Immunomodulatory activity of nivolumab in previously treated and untreated metastatic renal cell carcinoma (mRCC): Biomarker-based results from a randomized clinical trial.

http://abstracts.asco.org/144/AbstView_144_125914.html

3. Abstract 4504, Hans J. Hammers et al.

Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC).

http://abstracts.asco.org/144/AbstView_144_129458.html

4. Abstract 5003, Xabier Garcia-Albeniz et al.

Immediate versus deferred initiation of androgen deprivation therapy in prostate cancer patients with PSA-only relapse.

http://abstracts.asco.org/144/AbstView_144_131550.html

Oncology Practice covered this study from a premeeting press briefing.

5. Abstract 5007, Andrew J. Armstrong et al.

Primary, secondary, and quality-of-life endpoint results from PREVAIL, a phase 3 study of enzalutamide in men with metastatic, castration-resistant prostate cancer (mCRPC).

http://abstracts.asco.org/144/AbstView_144_127316.html

Dr. Walter M. Stadler is the Fred C. Buffett Professor of Medicine and Surgery; associate dean for clinical research; chief, section of hematology/oncology; and director, genitourinary program, University of Chicago.

1. Abstract LBA2, Christopher Sweeney et al.

Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): An ECOG-led phase III randomized trial.

http://abstracts.asco.org/144/AbstView_144_127755.html

2. Abstract 5012, Toni K. Choueiri et al.

Immunomodulatory activity of nivolumab in previously treated and untreated metastatic renal cell carcinoma (mRCC): Biomarker-based results from a randomized clinical trial.

http://abstracts.asco.org/144/AbstView_144_125914.html

3. Abstract 4504, Hans J. Hammers et al.

Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC).

http://abstracts.asco.org/144/AbstView_144_129458.html

4. Abstract 5003, Xabier Garcia-Albeniz et al.

Immediate versus deferred initiation of androgen deprivation therapy in prostate cancer patients with PSA-only relapse.

http://abstracts.asco.org/144/AbstView_144_131550.html

Oncology Practice covered this study from a premeeting press briefing.

5. Abstract 5007, Andrew J. Armstrong et al.

Primary, secondary, and quality-of-life endpoint results from PREVAIL, a phase 3 study of enzalutamide in men with metastatic, castration-resistant prostate cancer (mCRPC).

http://abstracts.asco.org/144/AbstView_144_127316.html

Dr. Walter M. Stadler is the Fred C. Buffett Professor of Medicine and Surgery; associate dean for clinical research; chief, section of hematology/oncology; and director, genitourinary program, University of Chicago.

1. Abstract LBA2, Christopher Sweeney et al.

Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): An ECOG-led phase III randomized trial.

http://abstracts.asco.org/144/AbstView_144_127755.html

2. Abstract 5012, Toni K. Choueiri et al.

Immunomodulatory activity of nivolumab in previously treated and untreated metastatic renal cell carcinoma (mRCC): Biomarker-based results from a randomized clinical trial.

http://abstracts.asco.org/144/AbstView_144_125914.html

3. Abstract 4504, Hans J. Hammers et al.

Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC).

http://abstracts.asco.org/144/AbstView_144_129458.html

4. Abstract 5003, Xabier Garcia-Albeniz et al.

Immediate versus deferred initiation of androgen deprivation therapy in prostate cancer patients with PSA-only relapse.

http://abstracts.asco.org/144/AbstView_144_131550.html

Oncology Practice covered this study from a premeeting press briefing.

5. Abstract 5007, Andrew J. Armstrong et al.

Primary, secondary, and quality-of-life endpoint results from PREVAIL, a phase 3 study of enzalutamide in men with metastatic, castration-resistant prostate cancer (mCRPC).

http://abstracts.asco.org/144/AbstView_144_127316.html

Dr. Walter M. Stadler is the Fred C. Buffett Professor of Medicine and Surgery; associate dean for clinical research; chief, section of hematology/oncology; and director, genitourinary program, University of Chicago.